中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
9期
1054-1055
,共2页
阿托伐他汀%CYP3A5%基因多态性%调脂效果
阿託伐他汀%CYP3A5%基因多態性%調脂效果
아탁벌타정%CYP3A5%기인다태성%조지효과
Atorvastatin%CYP3A5%Genetic polymorphism%Lipid regulation effect
目的 研究CYP3A5酶基因多态性与阿托伐他汀调脂疗效与安全性的临床效应个体差异的相关性.方法 47例高脂血症患者予阿托伐他汀片(10 mg,每日1次口服)治疗,疗程24周.分别于治疗前及疗程结束时空腹抽血检测血脂(TC、TG、LDL-C、HDL-C)肝酶及肌酸激酶水平.采用聚合酶链反应扩增及限制性片段长度多态性技术对患者CYP3A5酶基因进行分型.结果 按CYP3A5基因型分组,CYP3A5*1组22例(包括CYP3A5*1/*1型2例和CYP3A5*1/*3型20例),CYP3A5*3组(即CYP3A5*3/*3型)25例.治疗后,2组患者TC、LDL-C、TG水平均有有明下降(P＜0.05).CYP3A5*3组患者的TC、LDL-C下降幅度分别为(29.82±5.25)%和(35.35±4.06)%,明显大于CYP3A5*1组的(19.99±3.16)%和(25.84±2.31)%(均P＜0.05).CYP3A5*1组和CYP3A5*3组TG下降幅度分别为(31.81±4.68)%和(34.32±4.34)%,HDL-C升高幅度分别为(4.80±1.42)%和(5.65±1.76)%,2组差异无统计学意义(均P＞0.05).结论 CYP3A5酶基因多态性可能对阿托伐他汀调脂疗效有影响.
目的 研究CYP3A5酶基因多態性與阿託伐他汀調脂療效與安全性的臨床效應箇體差異的相關性.方法 47例高脂血癥患者予阿託伐他汀片(10 mg,每日1次口服)治療,療程24週.分彆于治療前及療程結束時空腹抽血檢測血脂(TC、TG、LDL-C、HDL-C)肝酶及肌痠激酶水平.採用聚閤酶鏈反應擴增及限製性片段長度多態性技術對患者CYP3A5酶基因進行分型.結果 按CYP3A5基因型分組,CYP3A5*1組22例(包括CYP3A5*1/*1型2例和CYP3A5*1/*3型20例),CYP3A5*3組(即CYP3A5*3/*3型)25例.治療後,2組患者TC、LDL-C、TG水平均有有明下降(P＜0.05).CYP3A5*3組患者的TC、LDL-C下降幅度分彆為(29.82±5.25)%和(35.35±4.06)%,明顯大于CYP3A5*1組的(19.99±3.16)%和(25.84±2.31)%(均P＜0.05).CYP3A5*1組和CYP3A5*3組TG下降幅度分彆為(31.81±4.68)%和(34.32±4.34)%,HDL-C升高幅度分彆為(4.80±1.42)%和(5.65±1.76)%,2組差異無統計學意義(均P＞0.05).結論 CYP3A5酶基因多態性可能對阿託伐他汀調脂療效有影響.
목적 연구CYP3A5매기인다태성여아탁벌타정조지료효여안전성적림상효응개체차이적상관성.방법 47례고지혈증환자여아탁벌타정편(10 mg,매일1차구복)치료,료정24주.분별우치료전급료정결속시공복추혈검측혈지(TC、TG、LDL-C、HDL-C)간매급기산격매수평.채용취합매련반응확증급한제성편단장도다태성기술대환자CYP3A5매기인진행분형.결과 안CYP3A5기인형분조,CYP3A5*1조22례(포괄CYP3A5*1/*1형2례화CYP3A5*1/*3형20례),CYP3A5*3조(즉CYP3A5*3/*3형)25례.치료후,2조환자TC、LDL-C、TG수평균유유명하강(P＜0.05).CYP3A5*3조환자적TC、LDL-C하강폭도분별위(29.82±5.25)%화(35.35±4.06)%,명현대우CYP3A5*1조적(19.99±3.16)%화(25.84±2.31)%(균P＜0.05).CYP3A5*1조화CYP3A5*3조TG하강폭도분별위(31.81±4.68)%화(34.32±4.34)%,HDL-C승고폭도분별위(4.80±1.42)%화(5.65±1.76)%,2조차이무통계학의의(균P＞0.05).결론 CYP3A5매기인다태성가능대아탁벌타정조지료효유영향.
Objective To study the correlationship between CYP3A5 enzyme genetic polymorphism and effectivity as well as security of Atorvastatin to provide reference for clinical usage. Methods Forty-seven aged patients with hypercholesterolemia were enrolled. Atorvastatin(10 mg/d) was given for treatment. All patients' serum level of TC, TG, LDL-C, aminotransferase and phosphocreatine before and after the 24 weeks' treatment were tested. PCR-RELP technique was adopted to analyze CYP3A5 enzyme gene of the patients. Results There were 22 cases who were divided in the CYP3A5 1 group(including 2 cases for CYP3A5 1/1 and twenty for CYP3A5 1/ 3) and 25 into the CYP3 A5 3 group. After Atorvastatin treatment, both group showed reduction in serum level ofTC, LDL-C, TG(P＜0.05). The reduction amplitude of serum TC and LDL-C level of CYP3A5 3 group was (29.82 ± 5.25) % and (35.35 ± 4.06) % respectively, which was higher than that of CYP3A5 1 group [(19. 99 ± 3.16) % and (25.84 ± 2.31) %]. Conclusion CYP3A5 enzyme genetic polymorphism may influence Atorvastatin treatment.
